NVAX - ノババックス (Novavax Inc.) ノババックス

 NVAXのチャート


 NVAXの企業情報

symbol NVAx
会社名 Novavax Inc. (ノババックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ノババックス(Novavax Inc.)は臨床段階のバイオ医薬品会社である。同社は組換えナノ粒子ワクチン及びアジュバントの発見・開発・商業化に焦点を当てる。同社は組換えワクチンセグメントの開発を通じて事業を行っている。同社は、組換えナノ粒子ワクチン技術を用いて、既知疾患及び新興疾患に対応するワクチン候補物質を製造する。同社の製品パイプラインは、呼吸器合胞体ウイルス(RSV)、季節性インフルエンザ、パンデミックインフルエンザおよびエボラウイルス(EBOV)の臨床開発におけるワクチン候補の感染症に焦点を当てる。同社の人用鉛アジュバントであるMatrix-Mは、パンデミックインフルエンザH7N9ワクチン候補のフェーズI / II臨床試験にある。また、第I相臨床試験でEBOVワクチン候補と併せてMatrix-Mを試験している。同社は中東呼吸器症候群(MERS)を含む感染性疾患で、前臨床段階の追加プログラムを開発している。   ノババックスは、臨床段階の米国バイオ医薬品企業。組換えナノ粒子ワクチンおよび抗原性補強剤の発見、開発、商業化に従事する。呼吸器合胞体ウイルス、季節性インフルエンザと新型インフルエンザのための臨床開発などの感染症に対象を当て遺伝子組み換えによるワクチンを開発する。   
本社所在地 20 Firstfield Road Garthersburg MD 20878 USA
代表者氏名 James Francis Young ジェームズ・フランシス・ヤング
代表者役職名 Independent Chairman of the Board
電話番号 +1 240-268-2000
設立年月日 1987年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 347人
url www.novavax.com
nasdaq_url https://www.nasdaq.com/symbol/nvax
adr_tso
EBITDA EBITDA(百万ドル) -165.13200
終値(lastsale) 2.065
時価総額(marketcap) 790052064.935
時価総額 時価総額(百万ドル) 723.09850
売上高 売上高(百万ドル) 39.19000
企業価値(EV) 企業価値(EV)(百万ドル) 874.46250
当期純利益 当期純利益(百万ドル) -186.29300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Novavax Inc. revenues increased 65% to $20.4M. Net loss increased 3% to $90.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 16% to $83.5M (expense) Labor_Related Expenses in R&D increase of 18% to $5.6M (expense).

 NVAXのテクニカル分析


 NVAXのニュース

   Επιτάχυνση του εμβολιασμού ζητούν ευρωβουλευτές από τους επικεφαλής των φαρμακευτικών  2021/03/01 05:51:00 Real Greece
Την σημασία που έχει η επιτάχυνση της παραγωγής και η πρόσβαση σε εμβόλια επεσήμαναν ευρωβουλευτές σε διευθύνοντες συμβούλους και εκπροσώπους κορυφαίων φαρμακευτικών εταιρειών, συμπεριλαμβανομένων των AstraZeneca, Moderna, CureVac, Novavax, Pfizer και Sanofi.  …
   Catat, Vaksinasi Mandiri Tak Boleh Gunakan 4 Jenis Vaksin Ini  2021/02/28 09:10:00 CNBC Indonesia
Program vaksinasi mandiri tidak akan menggunakan vaksin Sinovac, AstraZeneca, Novavax, dan Pfizer.
   Covid, i vaccini in arrivo (salvo intoppi): dal monodose Janssen a Novavax e Curevac. In fila per l’ok di Ema il russo Sputnik e Sinovac  2021/02/28 08:04:16 Il Fatto Quotidiano
Tra metà marzo e giugno potrebbero essere tre i composti approvati. Degli oltre 20 milioni di dosi attese in Italia per il primo trimestre ne sono state consegnate poco più di 5 milioni e 800mila L'articolo Covid, i vaccini in arrivo (salvo intoppi): dal monodose Janssen a Novavax e Curevac. In fila per l’ok di Ema il russo Sputnik e Sinovac proviene da Il Fatto Quotidiano .
   Novavax und Takeda: Lizenzdeal für COVID-19 Impfstoff  2021/02/26 13:45:09 4investors
Novavax hat einen Lizenzpartner für seinen COVID-19 Impfstoff NVX-CoV2373 an Land gezogen: Der japanische Takeda-Konzern wird Partner des …
   Russia & West Trade Blame For Vaccine 'Price Gouging' & Exploitation Of Africa  2021/02/26 10:45:00 Zero Hedge
Russia & West Trade Blame For Vaccine 'Price Gouging' & Exploitation Of Africa Westerners bringing 'benefits' to the African continent has long been met with deep suspicion and even hostility from local Africans, given the colonial legacy stemming especially from the 19th century 'scramble for Africa' period, and further a Cold War-dominated 20th century which witnessed CIA regime change and coup efforts in places like Congo, Ghana and Angola - in order to prevent left-leaning popular movements from turning to the Soviets. Africa was one of the major global hotspots in which Washington and the Kremlin quietly engaged in intense but quiet subterfuge against the other, which simultaneously involved a public propaganda war accusing the other of ravaging and exploiting Africa. And now a new 'Cold War' of sorts is beginning to play out on the vaccine front , with Financial Times in a bombshell investigation revealing this week the emerging issue of massive disparities in vaccine prices and availability - again in what's taking the form of competition between Russia and the West .
   Novavax: Konkurrenz für BioNTech, AstraZeneca und Co. auf dem 5. Kontinent | www.4investors.de  2021/01/08 18:15:37 4investors
Bei der Erforschung und Zulassung von Impfstoffen gegen Corona redet man in Europa vor allem von BioNTech, Moderna, AstraZeneca sowie Curevac/Bayer. In anderen
   Novavax Strikes Another Coronavirus Vaccine Supply Deal: Where Does The Company's Program Stand?  2021/01/08 16:50:08 Benzinga
Novavax, Inc. (NASDAQ: NVAX ) shares are higher Friday following a coronavirus vaccine supply deal the company announced with the Australian government. Deal Sealed: Novavax, based in Gaithersburg, Maryland, said late Thursday the Australian government has executed a purchase agreement to buy 51 million doses of NVX-CoV2373, the company's coronavirus vaccine candidate, with an option to buy an additional 10 million doses. This follows an agreement in principle the parties announced in November. Upon the vaccine candidate hitting efficacy and safety goals in ongoing pivotal trials, the company will work with the Australian drug regulator to obtain product approvals. The company expects to deliver the initial doses by mid-2021. Is this timeline a practically achievable target, given the delays the company experienced in the start of the late-stage trial? Here's a look at where Novavax' vaccine program stands. The Wait Extends: NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, created using the company's recombinant nanoparticle technology to generate antigen derived from the coronavirus spike protein.
   The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs  2021/01/08 07:25:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 7) …
   Biopharma Daily Stock Updates - 01/07/20  2021/01/08 05:55:33 AmpBioResearch
$XBI $149.21 (+4.11%) 📈 COVID: $NVAX (+3.56%) - Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine https://ir.novavax.com/news-releases/news-release-details/novavax-finalizes-agreement-commonwealth-australia-51-million PIPELINE: $SRPTA (+1.50%) - Sarepta Therapeutics An
   Australia enters agreement to buy 51 mln doses of Novavax's COVID-19 vaccine | Health  2021/01/07 23:33:29 Devdiscourse
(https://reut.rs/3npMLYe) The government will support Novavax to seek approval from the health regulator of Australia for its COVID-19 vaccine candidate, the company said.
   Vaccine Hopeful Novavax Could Be Worth a Shot | Markets Insider  2020/10/28 11:52:24 Markets Insider
Registration on or use of this site constitutes acceptance of our Terms of Service and Privacy Policy.
   COVID-19 vaccine: Novavax delays Phase 3 testing in U.S.  2020/10/27 18:58:58 United Press International
Maryland-based biotech firm Novavax on Tuesday announced it's delayed the start of its Phase 3 testing of a potential COVID-19 in North America.
   Novavax delays U.S. trial of COVID-19 vaccine to November | Health  2020/10/27 18:18:31 Devdiscourse
Novavax in August said it will supply 60 million doses of its coronavirus vaccine to the UK from as early as the first quarter of 2021. The company is also preparing to deliver 100 million doses to the United States by January after it was awarded $1.6 billion for its potential vaccine, and has also signed supply agreements with Canada and Japan.
   Novavax Rallies On Phase 3 Coronavirus Study Updates, Imminent Phase 2 Readout  2020/10/27 14:51:54 Benzinga
Novavax, Inc. (NASDAQ: NVAX ) issued … Full story available on Benzinga.com
   Covid-19 vaccine: Novavax delays US clinical trials to November  2020/10/27 14:45:26 Livemint
Novavax also says that data from a separate phase 3 trial being conducted in Britain was expected by the first quarter of 2021.Early-stage data had showed the vaccine produced high levels of antibodies against the novel coronavirus

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ノババックス NVAX Novavax Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)